Novo Nordisk slashes US prices for Wegovy, Ozempic as competition ramps up

(Sharecast News) - Danish pharma giant Novo Nordisk is to halve the US price of obesity drug Wegovy and slash the price of diabetes treatment Ozempic from next year as competition ramps up with rival drugmaker Eli Lilly.

From 1 January 2027, both Wegovy and Ozempic will have list prices of $675 for a monthly dose, down 50% and 35% on current prices, respectively.

The move, according to Novo Nordisk, is a concerted effort to improve patient access for both public and private payers "dealing with the complexities of the evolving US healthcare system".

"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices," said Novo Nordisk's executive vice president Jamey Millar.

"The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs."

The announcements come just one month after Eli Lilly launched a multi-dose KwikPen version of its blockbuster Zepbound weight-management, the most prescribed obesity drug in 2025, delivering a full month of treatment in one device.